|
Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. 〔(【引用サイトリンク】title=Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials )〕 Two phase II trials reported it was effective and well tolerated. Of the eight planned phase III clinical trials of weekly taspoglutide (four against exenatide, sitagliptin, insulin glargine, and pioglitazone), at least five were active in 2009.〔(【引用サイトリンク】title=Ipsen's Partner Roche Announces That Taspoglutide Meets Its Primary Endpoint In The First Phase III Clinical Trial )〕 Preliminary results in early 2010 were favourable.〔(【引用サイトリンク】title=Roche Reports Positive Data from Five Phase III Trials of Type 2 Diabetes Therapy )〕 (At least one of the eight planned phase III trials had not started recruiting by end 2009.) In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects. no new trials had been registered.〔(Clinical studies of taspoglutide )〕 ==Chemistry== Taspoglutide is the peptide with the sequence H2N-His-2-methyl-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-2-methyl-Ala-Arg-CONH2. In other words, it is the 8-(2-methylalanine)-35-(2-methylalanine)-36-L-argininamide derivative of the amino acid sequence 7–36 of human glucagon-like peptide I. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「taspoglutide」の詳細全文を読む スポンサード リンク
|